+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Dapagliflozin"

From
From
FARXIGA Market Size, Forecast, and Emerging Insight - 2032 - Product Thumbnail Image

FARXIGA Market Size, Forecast, and Emerging Insight - 2032

  • Report
  • April 2024
  • 30 Pages
  • Global
From
From
Sodium-glucose transporter 2 inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Sodium-glucose transporter 2 inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Diabetes Drug Intelligence Center 2012-2023 - Product Thumbnail Image

Diabetes Drug Intelligence Center 2012-2023

  • Report
  • June 2024
  • Global
From
From
From
From
From
From
From
From
From
From
From
Loading Indicator

Dapagliflozin is a drug used to treat endocrine and metabolic disorders. It belongs to a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, which work by blocking the reabsorption of glucose in the kidneys, leading to increased excretion of glucose in the urine. This helps to reduce blood sugar levels in people with type 2 diabetes. Dapagliflozin is also used to reduce the risk of cardiovascular events in adults with type 2 diabetes. Dapagliflozin is available in both tablet and oral solution form and is typically taken once daily. Common side effects include urinary tract infections, increased urination, and genital yeast infections. The Dapagliflozin market is highly competitive, with several major pharmaceutical companies offering the drug. These include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, and Novo Nordisk. Show Less Read more